1. As of noon trading, Express Scripts ( ESRX) is up $0.59 (0.9%) to $62.51 on light volume. Thus far, 1.4 million shares of Express Scripts exchanged hands as compared to its average daily volume of 4.9 million shares. The stock has ranged in price between $61.52-$62.53 after having opened the day at $61.53 as compared to the previous trading day's close of $61.92.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $50.5 billion and is part of the health care sector. The company has a P/E ratio of 36.8, above the S&P 500 P/E ratio of 17.7. Shares are up 14.7% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Express Scripts Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Zimmer Biomet's Prognosis Is Promising

Zimmer Biomet's Prognosis Is Promising

St. Jude Buying Thoratec Could Resusitate Medtech M&As

Analysts' Actions -- AT&T, Fitbit, Netflix and More

Barbarian At The Gate: Zimmer Holdings (ZMH)

Deal Delay Minor Obstacle for Zimmer

Deal Delay Minor Obstacle for Zimmer